Antibiotic Resistance Market

Antibiotic Resistance Market Overview

The Antibiotic Resistance Market Size was valued at USD 12.53 billion in 2023 and is projected to grow from USD 13.19 Billion in 2024 to USD 17.5 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.59% during the forecast period (2024 - 2032).Growing public health concern worldwide, with increasing rates of bacterial infections that are resistant to traditional antibiotics are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Key drivers of the market include the rising prevalence of antibiotic-resistant diseases in both developed and developing nations and a shift in prescription patterns toward newly released medicines. Additionally, innovative therapy development is expected to be driven by the rising engagement of government and non-government organisations. To speed up the process of creating new medicines, the World Health Organization (WHO) and others are working hard to secure funding.

Antibiotic use is on the rise in low and medium income nations, pharmaceutical companies are investing heavily in R&D, and the incidence of infectious diseases is on the rise, all of which contribute to the growth of the worldwide antibiotics market. Profitable opportunities have opened up in developed markets as a result of the large investments and technological advances made by major players in the manufacture of numerous end-use items. Growth in the antibiotic resistance market is also anticipated during the projected period, thanks to improvements in diet, medicine, and immunization. Antibiotic-resistant microbial illnesses are anticipated to fuel market expansion, as is the identification of cutting-edge candidate compounds and the release of novel combination medicines to treat them.

As more organizations, both public and private, work to find alternatives to antibiotics, the market should continue to expand. BARDA is just one example of an international organization that is present in developed markets and stimulates them by providing financial aid to biotech businesses so that they can finish preliminary research on novel antibiotic-resistant sickness treatments. This is expected to create fresh avenues for earning money in the global Antibiotic Resistance industry. Over the forecast period, the market is expected to expand profitably thanks to the significant investments made by major organizations and the recent advances in the creation of new technologies.

Over the projection period, the market should benefit from the strong pipeline items. Strong therapeutic candidates for the treatment of antibiotic-resistant diseases are in the late stages of clinical trials at companies including Melinta Therapeutics, Basilea Pharmaceutica Ltd., Pfizer Inc., and Merck & Co., Inc.

In June 2023, Alkem Laboratories, a pharmaceutical company, announced the release of an antibiotic medication to combat multidrug-resistant illnesses. Zidavi, the company's flagship medication, is a new combination of ceftazidime and avibactam that treats a wide range of conditions, including severe urinary tract infections. Zidavi, the company's flagship medication, is a new combination of ceftazidime and avibactam that treats a wide range of conditions, including severe urinary tract infections. Zidavi (ceftazidime-avibactam) has shown promise as a treatment for infections caused by MDR bacteria, according to the data currently available.

Antibiotic Resistance Market Trends

• Increasing prevalence of bacterial infections to boost market growth

The growing number of bacterial infections worldwide is a key driver of the antibiotic resistance market. According to the World Health Organization (WHO), antibiotic resistance is one of the biggest threats to health, with an estimated 700,000 deaths each year due to antibiotic-resistant infections. There has been a decrease in the development of new antibiotics in recent years, which has led to an increase in antibiotic-resistant infections. According to the Pew Charitable Trusts, only 10 new antibiotics were approved between 2010 and 2018. Overuse and misuse of antibiotics in both humans and animals can contribute to the development of antibiotic resistance.

According to the Centers for Disease Control and Prevention (CDC), approximately 30% of antibiotics prescribed in the US are unnecessary. Additionally, pharmaceutical companies and government agencies are investing more in antibiotic research to develop new drugs to combat antibiotic-resistant infections. In 2020, the US National Institutes of Health (NIH) announced a $9 million investment in antibiotic resistance research.

Moreover, the increasing prevalence of antibiotic-resistant infections, limited new antibiotic development, overuse and misuse of antibiotics, and increasing investment in antibiotic research are key drivers of the antibiotic resistance market.

Antibiotic Resistance Market Segment Insights

Antibiotic Resistance Market Drug Class Insights

The Antibiotic Resistance Market segmentation, based on drug class, includes Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, and Combination Therapies. The lipoglycopeptides segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2032. This is due to the growing prevalence of antibiotic-resistant bacterial infections and the need for effective treatments, particularly in critically ill patients. The development of new lipoglycopeptide antibiotics and alternative treatments, such as phage therapy and immunotherapy, may also play a role in the future of this market segment.

In 2020: Theravance Biopharma announced positive results from a Phase 3 clinical trial of its investigational lipoglycopeptide antibiotic, Telavancin, for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). The trial met its primary endpoint of non-inferiority compared to the current standard of care antibiotic, vancomycin, and demonstrated a safety profile consistent with previous trials of telavancin. These positive results suggest that telavancin may be an effective treatment option for patients with HABP and VABP, and may help to address the growing issue of antibiotic resistance in healthcare settings.

Antibiotic Resistance Market Disease Insights

The Antibiotic Resistance Market data has been bifurcated by disease into complicated urinary tract infection, blood stream infections, complicated intra-abdominal infections, clostridium difficile infections, acute bacterial skin, and skin structure infections. The blood stream infections disease segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Bloodstream infections, also known as sepsis, are a serious and potentially life-threatening condition caused by the growth of infectious organisms in the bloodstream. According to the Centers for Disease Control and Prevention, approximately 1.7 million cases of sepsis occur each year in the United States, with a mortality rate of around 15-30%. Effective prevention and management of bloodstream infections are critical to reducing their impact on public health.

Figure 1: Antibiotic Resistance Market, by Disease, 2023 & 2032 (USD Billion)

Antibiotic Resistance Market Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Antibiotic Resistance Market accounted for USD 5.45 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. The region is driven by the high prevalence of antibiotic-resistant infections in these regions and the availability of advanced healthcare infrastructure. Additionally, government initiatives and funding to support research and development of new antibiotics are expected to drive market growth in these regions. Further, the USA Antibiotic Resistance Market held the largest market share, and the Canada Antibiotic Resistance Market was the fastest growing market in the North American region due to the high demand for Antibiotic Resistance Market and the presence of several major manufacturers in the country.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ANTIBIOTIC RESISTANCE MARKET SHARE BY REGION 2023 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Antibiotic Resistance Market accounts for the second-largest market share. The antibiotic resistance market is expected to grow significantly over the forecast period due to the increasing prevalence of antibiotic-resistant infections and the growing demand for effective treatment options.

The Asia-Pacific Antibiotic Resistance Market is expected to grow at the fastest CAGR from 2024 - 2032. The market is driven by the increasing prevalence of infectious diseases, rising healthcare expenditure, and the growing demand for effective antibiotic therapies. Moreover, China Antibiotic Resistance Market held the largest market share, and the India Antibiotic Resistance Market was the fastest growing market in the Asia-Pacific region.

Antibiotic Resistance Market Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the Antibiotic Resistance Market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Antibiotic Resistance Market industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the Antibiotic Resistance Market industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Antibiotic Resistance Market industry has provided innovative products with some of the most significant benefits. The Antibiotic Resistance Market major player such as Achaogen Inc. (US), Basilea Pharmaceutica Ltd. (Switzerland), MELINTA THERAPEUTICS INC. (US), PARATEK therapeutics (US), Seres Therapeutics (US), Theravance Biopharma (UK), Entasis Therapeutics (US), Tetraphase Pharmaceuticals (US), Nabriva Therapeutics plc (Ireland), NEMESIS BIOSCIENCE LTD (UK) and others are working to expand the market demand by investing in research and development activities.

Achaogen Inc. was a biopharmaceutical company focused on the development and commercialization of antibacterial treatments for multidrug-resistant (MDR) gram-negative infections. In 2018, the company made headlines for receiving FDA approval for its antibiotic plazomicin, which was designed to treat certain MDR gram-negative infections, including complicated urinary tract infections. However, in 2019, Achaogen filed for bankruptcy due to financial difficulties, which highlighted the challenges faced by companies working to develop new antibiotics in the face of rising antibiotic resistance. Achaogen's bankruptcy also raised concerns about the future of antibiotic development and the need for increased investment in this area to address the growing threat of antibiotic-resistant infections. The failure of Achaogen underscores the need for sustained investment in research and development of new antibiotics to combat the rising tide of antibiotic resistance.

Basilea Pharmaceutica Ltd. is a Swiss biopharmaceutical company focused on the research, development, and commercialization of antibacterial and antifungal agents to address the growing threat of antibiotic resistance. The company was founded in 2000 and is headquartered in Basel, Switzerland. One recent news related to Basilea Pharmaceutica and antibiotic resistance is the FDA approval of its new antibiotic, Ceftobiprole. In early 2020, Ceftobiprole was approved by the FDA for the treatment of community-acquired bacterial pneumonia (CABP) caused by certain susceptible gram-positive and gram-negative bacteria, including those that are resistant to other antibiotics. The approval of Ceftobiprole was a significant milestone for Basilea Pharmaceutica and demonstrated the company's commitment to developing new antibiotics to address the threat of antibiotic resistance. Additionally, Basilea Pharmaceutica has ongoing research and development programs focused on the development of novel antibiotics and antifungal agents to address the growing threat of antibiotic resistance. The company is also collaborating with other organizations and institutions to advance research in this area and promote the development of new treatments for antibiotic-resistant infections.

In November 2022, the Antimicrobial Resistance Multi-Stakeholder Partnership Platform became live in November 2022 to deal with the worldwide epidemic of the same name. The United Nations' Food and Agriculture Organization (FAO), United Nations Environment Programme (UNEP), World Health Organization (WHO), and World Organisation for Animal Health (WOAH), collectively known as the Quadripartite, are working together on this initiative to highlight the dangers that antimicrobial resistance (AMR) poses to people, animals, plants, ecosystems, and ways of life.

Key Companies in the Antibiotic Resistance Market includes

• Achaogen Inc. (US)
• Basilea Pharmaceutica Ltd. (Switzerland)
• MELINTA THERAPEUTICS INC. (US)
• PARATEK therapeutics (US)
• Seres Therapeutics (US)
• Theravance Biopharma (UK)
• Entasis Therapeutics (US)
• Tetraphase Pharmaceuticals (US)
• Nabriva Therapeutics plc (Ireland)
• NEMESIS BIOSCIENCE LTD (UK)

Antibiotic Resistance Market Industry Developments

2021:Spero Therapeutics received FDA Fast Track designation in 2021 for its new antibiotic SPR206, which is being developed for the treatment of complicated urinary tract infections caused by multidrug-resistant gram-negative bacteria.

2020:Entasis Therapeutics received FDA approval in 2020 for its new antibiotic Zoliflodacin for the treatment of uncomplicated urogenital gonorrhea.

2020:Basilea Pharmaceutica Ltd. received FDA approval in early 2020 for its new antibiotic Ceftobiprole for the treatment of community-acquired bacterial pneumonia caused by certain susceptible gram-positive and gram-negative bacteria, including those that are resistant to other antibiotics.

Antibiotic Resistance Market Segmentation

Antibiotic Resistance Market Drug Class Outlook

• Oxazolidinones
• Lipoglycopeptides
• Tetracyclines
• Cephalosporins
• Combination Therapies

Antibiotic Resistance Market Disease Outlook

• Complicated Urinary Tract Infection
• Blood Stream Infections
• Complicated Intra-Abdominal Infections
• Clostridium Difficile Infections
• Acute Bacterial Skin and Skin Structure Infections

Antibiotic Resistance Market Pathogen Outlook

• Staphylococcus Aureus
• Streptococcus Pneumoniae
• Acinetobacter
• Enterococcus
• Hemophilus Influenzae

Antibiotic Resistance Market End User Outlook

• Hospitals & Clinics
• Research Organizations

Antibiotic Resistance Market Regional Outlook

• US
• Canada

• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe

• China
• Japan
• India
• Australia
• South Korea
• Australia
• Rest of Asia-Pacific

• Middle East
• Africa
• Latin America